Halofenate versus clofibrate in the management of true diabetes insipidus.

The antidiuretic effect of two chemically related drugs, clofibrate and halofenate, was tested in a patient with pitressin-sensitive diabetes insipidus. The conventional daily dosage of 2 g clofibrate failed to control the symptoms of this patient; in order to obtain an adequate response the dosage had to be increased to 4 g daily.Halofenate at a dosage of 2 g daily, an amount equivalent in hypolipidemic activity to 4 g per day of clofibrate, significantly reduced water intake and output, while urinary osmolarity was markedly increased.It is concluded that (1) the antidiuretic effect of clofibrate may be dose-related, and that (2) halofenate also possesses some antidiuretic activity.

[1]  W. Mroczek,et al.  Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent. , 1972, The American journal of cardiology.

[2]  W. Mroczek,et al.  Comparison of clonidine and methyldopa in hypertensive patients receiving a diuretic. A double-blind crossover study. , 1972, The American journal of cardiology.

[3]  S. Hoobler,et al.  Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients. , 1972, American heart journal.

[4]  K. E. Kim,et al.  Clonidine: a new antihypertensive agent. , 1971, The American journal of cardiology.

[5]  S. Hoobler,et al.  Clonidine hydrochloride in the treatment of hypertension. , 1971, The American journal of cardiology.

[6]  P. Samet,et al.  Effects of clonidin and chlorthalidone on blood pressure and glucose tolerance in hypertensive patients. , 1971, Current therapeutic research, clinical and experimental.

[7]  A. Schwartz,et al.  Antihypertensive Effect of Clonidine , 1971, Circulation research.

[8]  J. Morledge,et al.  Antihypertensive effect of a new imidazoline compound (clonidine) and chlorthalidone, individually and in combination. , 1970, The American journal of cardiology.

[9]  H. Perry,et al.  Clonidine (Catapres): a new antihypertensive agent. , 1970, Current therapeutic research, clinical and experimental.

[10]  L. Siitonen,et al.  [Treatment of hypertension with clonidine]. , 1970, Duodecim; laaketieteellinen aikakauskirja.

[11]  J. Raftos.  THE USE OF “CATAPRES” IN THE TREATMENT OF SEVERE HYPERTENSION , 1969, The Medical journal of Australia.

[12]  A. Muir,et al.  Circulatory effects at rest and exercise of clonidine, an imidazoline derivative with hypotensive properties. , 1969, Lancet.

[13]  S. Hoobler,et al.  Clinical observations on a new antihypertensive drug, 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride. , 1969, American heart journal.

[14]  L. Hellman,et al.  REDUCTION OF CHOLESTEROL AND LIPIDS IN MAN BY ETHYL P-CHLOROPHENOXYISOBUTYRATE. , 1963, Annals of internal medicine.

[15]  R. P. Howard,et al.  EFFECTS OF ETHYL CHLOROPHENOXYISOBUTYRATE, ALONE OR WITH ANDROSTERONE (ATROMID) ON SERUM LIPIDS, LIPOPROTEINS AND RELATED METABOLIC PARAMETERS IN NORMAL AND HYPERLIPIDEMIC SUBJECTS. , 1963, Journal of Atherosclerosis Research.

[16]  W. Inman,et al.  MULTICENTRE TRIAL IN THE UNITED KINGDOM AND IRELAND OF A MIXTURE OF ETHYL CHLOROPHENOXYISOBUTYRATE AND ANDROSTERONE (ATROMID). A PRELIMINARY REPORT. , 1963, Journal of atherosclerosis research.

[17]  J. Nabarro,et al.  THE EFFECTS OF ATROMID ON THE METABOLISM OF ADRENAL STEROIDS AND ON PLASMA LIPID FRACTIONS. , 1963, Journal of atherosclerosis research.

[18]  J. Thorp.  EXPERIMENTAL EVALUATION OF AN ORALLY ACTIVE COMBINATION OF ANDROSTERONE WITH ETHYL CHLOROPHENOXYISOBUTYRATE , 1962 .

[19]  M. Oliver.  Reduction of serum-lipid and uric-acid levels by an orally active androsterone. , 1962, Lancet.